Comparison
Argireline vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Research other
CAS no.
616204-22-9
57773-63-4
Molecular weight
888.99 g/mol
1311.45 g/mol
Half-life
no data
3 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
4
of which in humans
2
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
3